A general-purpose Claude Code action for GitHub PRs and issues that can answer questions and implement code changes. This action listens for a trigger phrase in comments and activates Claude act on ...

SNY closed Thursday's trading at $52.35, up 0.69%. GSK plc (GSK) The FDA decision on GSK's prefilled syringe presentation of Shingrix vaccine for the prevention of shingles is expected on June 20 ...

1 Developed by Samsung Bioepis and commercialized by Organon, the parties’ high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and high-concentration prefilled syringe are being ...

The expanded interchangeability now applies to the 40mg prefilled syringe and the 40mg and 80mg autoinjectors, in addition to the 20mg and 80mg prefilled syringes. The Food and Drug Administration ...

To help with the vehicle recovery and minimize further property damage, Congers Collision responded with a rotator tow truck, a specialized vehicle designed to handle complex extractions. No further ...

To help with the vehicle recovery and minimize further property damage, Congers Collision responded with a rotator tow truck, a specialized vehicle designed to handle complex extractions. No further ...

The discounted doses require patients to manually draw the medication from a vial with a syringe, adding an extra step compared to the prefilled injector pens. Experts point to several forces ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial ...

Sibeprenlimab would be offered in a prefilled syringe for subcutaneous injection. The PDUFA target action date is Nov. 28, 2025. The FDA has accepted for priority review the biologics license ...

The FDA target action date (PDUFA date) is set for November 28, 2025 If approved, sibeprenlimab would offer patients a convenient single-dose prefilled syringe for subcutaneous injection every four ...

8 HADLIMA was first approved by the FDA in 2019 as a low-concentration (40 mg/0.8 mL) formulation of prefilled syringe and autoinjector. The high-concentration (40 mg/0.4 mL) formulation of prefilled ...